Comparative efficacy of individual renin-Angiotensin system inhibitors on major renal outcomes in diabetic kidney disease

A network meta-Analysis

Juyu Cai, Xianxi Huang, Zhongsheng Zheng, Qing Lin, Mian Peng, Daoqian Shen

Research output: Contribution to journalArticle

Abstract

Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two drug classes with well-documented renal protective effects. However, whether there is any difference among individual drugs remains unknown. In this study, we aimed to compare the efficacy of individual ACEIs/ARBs on major renal outcomes in adults with diabetic kidney disease (DKD). Methods We conducted a Bayesian-framework network meta-Analysis with a random effects model. We searched PubMed, Embase, Scopus, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov for clinical trials of ACEIs or ARBs as monotherapy compared with other conventional antihypertensive drugs or placebo. Primary outcomes were end-stage renal disease (ESRD) and albuminuria/proteinuria (including change in albuminuria/proteinuria, progression to macroalbuminuria and remission to normoalbuminuria). Secondary outcome was doubling of serum creatinine levels. We also assessed for hyperkalemia, cough and angioedema/edema. International prospective register of systematic reviews (PROSPERO) registration CRD42016036997. Results A total of 100 studies with data for 22 365 DKD patients, the majority of whom had type 2 diabetes, were included. Individual ACEIs and ARBs at goal doses showed no significant differences in ESRD and doubling of serum creatinine levels. They also shared similar effects on albuminuria/proteinuria reduction and progression or remission of albuminuria. When combining three outcomes of albuminuria/proteinuria as a single endpoint, most ACEIs/ARBs consistently showed favorable antiproteinuric effect, with little difference in the possibility of being the superior treatment for improving albuminuria/proteinuria. Primary outcomes did not change substantially in meta-regressions and sensitivity analyses. Findings were limited by lack of dose equivalence and paucity of data for some outcomes. Conclusions Based on the available evidence, individual ACEIs and ARBs at goal doses appeared to have no or little differences in their effect on major renal outcomes.

Original languageEnglish (US)
Pages (from-to)1968-1976
Number of pages9
JournalNephrology Dialysis Transplantation
Volume33
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Albuminuria
Angiotensin Receptor Antagonists
Diabetic Nephropathies
Renin-Angiotensin System
Angiotensin-Converting Enzyme Inhibitors
Proteinuria
Kidney
Chronic Kidney Failure
Creatinine
Angioedema
Hyperkalemia
Serum
Cough
PubMed
Individuality
Pharmaceutical Preparations
Type 2 Diabetes Mellitus
Antihypertensive Agents
Network Meta-Analysis
Edema

Keywords

  • ACEI
  • ARB
  • diabetic kidney disease
  • network meta-Analysis

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Comparative efficacy of individual renin-Angiotensin system inhibitors on major renal outcomes in diabetic kidney disease : A network meta-Analysis. / Cai, Juyu; Huang, Xianxi; Zheng, Zhongsheng; Lin, Qing; Peng, Mian; Shen, Daoqian.

In: Nephrology Dialysis Transplantation, Vol. 33, No. 11, 01.11.2018, p. 1968-1976.

Research output: Contribution to journalArticle

@article{5d4f35fd698641b5b9ff008423254971,
title = "Comparative efficacy of individual renin-Angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: A network meta-Analysis",
abstract = "Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two drug classes with well-documented renal protective effects. However, whether there is any difference among individual drugs remains unknown. In this study, we aimed to compare the efficacy of individual ACEIs/ARBs on major renal outcomes in adults with diabetic kidney disease (DKD). Methods We conducted a Bayesian-framework network meta-Analysis with a random effects model. We searched PubMed, Embase, Scopus, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov for clinical trials of ACEIs or ARBs as monotherapy compared with other conventional antihypertensive drugs or placebo. Primary outcomes were end-stage renal disease (ESRD) and albuminuria/proteinuria (including change in albuminuria/proteinuria, progression to macroalbuminuria and remission to normoalbuminuria). Secondary outcome was doubling of serum creatinine levels. We also assessed for hyperkalemia, cough and angioedema/edema. International prospective register of systematic reviews (PROSPERO) registration CRD42016036997. Results A total of 100 studies with data for 22 365 DKD patients, the majority of whom had type 2 diabetes, were included. Individual ACEIs and ARBs at goal doses showed no significant differences in ESRD and doubling of serum creatinine levels. They also shared similar effects on albuminuria/proteinuria reduction and progression or remission of albuminuria. When combining three outcomes of albuminuria/proteinuria as a single endpoint, most ACEIs/ARBs consistently showed favorable antiproteinuric effect, with little difference in the possibility of being the superior treatment for improving albuminuria/proteinuria. Primary outcomes did not change substantially in meta-regressions and sensitivity analyses. Findings were limited by lack of dose equivalence and paucity of data for some outcomes. Conclusions Based on the available evidence, individual ACEIs and ARBs at goal doses appeared to have no or little differences in their effect on major renal outcomes.",
keywords = "ACEI, ARB, diabetic kidney disease, network meta-Analysis",
author = "Juyu Cai and Xianxi Huang and Zhongsheng Zheng and Qing Lin and Mian Peng and Daoqian Shen",
year = "2018",
month = "11",
day = "1",
doi = "10.1093/ndt/gfy001",
language = "English (US)",
volume = "33",
pages = "1968--1976",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Comparative efficacy of individual renin-Angiotensin system inhibitors on major renal outcomes in diabetic kidney disease

T2 - A network meta-Analysis

AU - Cai, Juyu

AU - Huang, Xianxi

AU - Zheng, Zhongsheng

AU - Lin, Qing

AU - Peng, Mian

AU - Shen, Daoqian

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two drug classes with well-documented renal protective effects. However, whether there is any difference among individual drugs remains unknown. In this study, we aimed to compare the efficacy of individual ACEIs/ARBs on major renal outcomes in adults with diabetic kidney disease (DKD). Methods We conducted a Bayesian-framework network meta-Analysis with a random effects model. We searched PubMed, Embase, Scopus, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov for clinical trials of ACEIs or ARBs as monotherapy compared with other conventional antihypertensive drugs or placebo. Primary outcomes were end-stage renal disease (ESRD) and albuminuria/proteinuria (including change in albuminuria/proteinuria, progression to macroalbuminuria and remission to normoalbuminuria). Secondary outcome was doubling of serum creatinine levels. We also assessed for hyperkalemia, cough and angioedema/edema. International prospective register of systematic reviews (PROSPERO) registration CRD42016036997. Results A total of 100 studies with data for 22 365 DKD patients, the majority of whom had type 2 diabetes, were included. Individual ACEIs and ARBs at goal doses showed no significant differences in ESRD and doubling of serum creatinine levels. They also shared similar effects on albuminuria/proteinuria reduction and progression or remission of albuminuria. When combining three outcomes of albuminuria/proteinuria as a single endpoint, most ACEIs/ARBs consistently showed favorable antiproteinuric effect, with little difference in the possibility of being the superior treatment for improving albuminuria/proteinuria. Primary outcomes did not change substantially in meta-regressions and sensitivity analyses. Findings were limited by lack of dose equivalence and paucity of data for some outcomes. Conclusions Based on the available evidence, individual ACEIs and ARBs at goal doses appeared to have no or little differences in their effect on major renal outcomes.

AB - Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two drug classes with well-documented renal protective effects. However, whether there is any difference among individual drugs remains unknown. In this study, we aimed to compare the efficacy of individual ACEIs/ARBs on major renal outcomes in adults with diabetic kidney disease (DKD). Methods We conducted a Bayesian-framework network meta-Analysis with a random effects model. We searched PubMed, Embase, Scopus, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov for clinical trials of ACEIs or ARBs as monotherapy compared with other conventional antihypertensive drugs or placebo. Primary outcomes were end-stage renal disease (ESRD) and albuminuria/proteinuria (including change in albuminuria/proteinuria, progression to macroalbuminuria and remission to normoalbuminuria). Secondary outcome was doubling of serum creatinine levels. We also assessed for hyperkalemia, cough and angioedema/edema. International prospective register of systematic reviews (PROSPERO) registration CRD42016036997. Results A total of 100 studies with data for 22 365 DKD patients, the majority of whom had type 2 diabetes, were included. Individual ACEIs and ARBs at goal doses showed no significant differences in ESRD and doubling of serum creatinine levels. They also shared similar effects on albuminuria/proteinuria reduction and progression or remission of albuminuria. When combining three outcomes of albuminuria/proteinuria as a single endpoint, most ACEIs/ARBs consistently showed favorable antiproteinuric effect, with little difference in the possibility of being the superior treatment for improving albuminuria/proteinuria. Primary outcomes did not change substantially in meta-regressions and sensitivity analyses. Findings were limited by lack of dose equivalence and paucity of data for some outcomes. Conclusions Based on the available evidence, individual ACEIs and ARBs at goal doses appeared to have no or little differences in their effect on major renal outcomes.

KW - ACEI

KW - ARB

KW - diabetic kidney disease

KW - network meta-Analysis

UR - http://www.scopus.com/inward/record.url?scp=85056031601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056031601&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfy001

DO - 10.1093/ndt/gfy001

M3 - Article

VL - 33

SP - 1968

EP - 1976

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 11

ER -